Key Client Fiduciary Advisors’s Cytosorbents CTSO Stock Holding History
Bought
Maintained
Sold
Other funds holding CTSO
CM
Key Client Fiduciary Advisors's CTSO Position: Q3 2026 in Review
Key Client Fiduciary Advisors sold out of Cytosorbents (CTSO) in Q3 2026, closing a stake of 3,923 shares — an estimated $29.3K sold.
Key Client Fiduciary Advisors first reported a position in CTSO in Q2 2022 and held it in 17 quarters. The position peaked at $100K in Q2 2025. 28 funds tracked by Wall St. Rank hold CTSO as of Q3 2026.
- Key Client Fiduciary Advisors reported no remaining Cytosorbents position as of Q3 2026 after selling out during the quarter.
- Key Client Fiduciary Advisors sold 3,923 Cytosorbents shares in Q3 2026, an estimated $29.3K.
- Key Client Fiduciary Advisors first reported a position in Cytosorbents in Q2 2022 and held it in 17 quarters.
- Key Client Fiduciary Advisors's Cytosorbents position peaked at $100K in Q2 2025.
- 28 funds tracked by Wall St. Rank held Cytosorbents as of Q3 2026.
Based on Key Client Fiduciary Advisors's 13F filing for Q3 2026, filed 19 Oct 2026.